Anupam Rasayan India Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/w2noef5k1viahzkp6e7gpteu.pdf

Key Takeaways


Demand Environment & Revenue Decline

Thakkar: "We anticipate that the stabilization of demand should start from Q1 FY '25 and it should only consolidate as you go further."

Pipeline & New Business


Margins & Mix

Desai: "Anupam Rasayan will be investing Rs 59 crores towards setting up a hybrid power plant of 9.6 megawatt... This initiative will help us reduce our energy cost of approximately Rs 15 crores per year."

Balance Sheet & Capital Allocation

Thakkar: "Today, my long-term debt would be share less than 400. And I think once we do this, the balance amount comes in, we should be going to zero debt in terms of long-term debt."

CAPEX & Capacity


Guidance & Commitments

CommitmentSpecificsTimeline
Demand stabilizationDestocking ends; demand stabilizes and consolidatesQ4 FY24 end, Q1 FY25 start
New molecule ramp11 molecules launched in 9M FY24 begin contributingGradual ramp through FY25 and FY26
LOI commercializationMost molecules from recent LOIs commercializedWithin two years (one in FY24, one from CY25, one from CY25-26)
CAPEX completionBalance of ₹670 cr plan incurredNext two quarters (by H1 FY25)
Long-term debtZero long-term debtWithin 18 months
Interest saving~₹24 cr reduction in interest costFY25
Energy cost reduction₹15 cr per year saving from hybrid power plantOn commissioning (investment underway)
Revenue contribution from new launchesContribution moving into the 20s (percent of revenue)FY25 and beyond

Key Metrics

MetricQ3 FY24
Revenue (consolidated)₹298 cr, down 23% YoY
Revenue (standalone) decline driverVolume-driven, price largely stable
EBITDA margin (standalone)30.1%
EBITDA margin (consolidated)27%, flat YoY
Profit after tax (consolidated)₹26 cr, vs ₹554 cr in Q3 FY23
9M FY24 revenue (consolidated)₹1,092 cr, down 1% YoY
9M FY24 EBITDA margin (consolidated)28%
9M FY24 profit after tax (consolidated)₹127 cr, down 12% YoY
9M FY24 revenue mixLife Sciences 91%, Specialty Chemicals 9%
9M FY24 customer concentrationTop 10 customers 77% of revenue, across 23 products
Exports share55–56% of quarterly revenue
New molecules commercialized in Q36 (4 fluorination series, 2 from signed LOIs/contracts)
New molecules commercialized in 9M FY2411
LOI signed during quarter$61 mn (₹507 cr) over 9 years, with a Japanese chemical company
CAPEX incurred in 9M FY24₹381 cr out of ₹670 cr planned
Cash and cash equivalents₹577 cr as of 31 Dec 2023
Long-term debt (as of call date)Less than ₹400 cr; external debt ~₹300–310 cr
Debt repaid from fundraise₹198 cr till date
Estimated interest saving for FY25~₹24 cr
Revenue capacity from current assets₹1,700–1,800 cr
Pharma revenue contribution outlook (FY25)Double-digit, higher teens or above
Polymer & other specialty contribution outlook (FY25)15–20% of portfolio
Fluorination contribution outlook (FY25)In the 20s (percent), if not more